Today I have Linda Tempelman, CEO of Persista Bio. With a PhD in Chemical Engineering from Cornell University and extensive experience in the biotech sector, Dr. Tempelman leads a team that’s breaking through barriers in cell therapy.Persista Bio’s pioneering O2Line™ system is designed to overcome immune rejection and support the long-term viability of therapeutic cells. Focused on enabling advanced treatments for chronic conditions like Type 1 Diabetes, their work has the potential to replace traditional therapies and pave the way for a new era of patient care. This could also eradicate diabetes!Join us as we explore Dr. Tempelman’s journey, the innovative work of Persista Bio, and the transformative impact their technology could have on healthcare. www.linkedin.com/in/ltempelman/www.persistabio.comFind me on LinkedIn @ www.linkedin.com/in/krev/www.therevellgroup.com

Ver todos los episodios